摘要
目的:观察达格列净联合二甲双胍治疗治疗初诊2型糖尿病(T2DM)患者的效果。方法:选取2021年5月至2023年4月该院收治的106例初诊T2DM患者进行前瞻性研究,根据随机数字表法将其分为观察组(n=53)与对照组(n=53)。对照组给予二甲双胍治疗,观察组在对照组基础上联合达格列净治疗,比较两组临床疗效、治疗前后糖代谢指标[餐后2 h血糖(2hPG)、糖化血红蛋白(HbAlc)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、胰岛素分泌指数(HOMA-β)]水平、炎性指标[C反应蛋白(CRP)、同型半胱氨酸(Hcy)]水平和不良反应发生率。结果:观察组治疗总有效率为94.34%(50/53),高于对照组的81.13%(43/53),差异有统计学意义(P<0.05);治疗后,两组HbAlc、2hPG、HOMA-IR水平均低于治疗前,且观察组低于对照组,两组FINS、HOMA-β水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组CRP、Hcy水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:达格列净联合二甲双胍治疗初诊T2DM患者可提高治疗总有效率,改善糖代谢指标水平,降低炎性指标水平,其效果优于单纯二甲双胍治疗。
Objective:To observe effects of Dapagliflozin combined with Metformin in treatment of patients with newly diagnosed type 2 diabetes mellitus(T2DM).Methods:A prospective study was conducted on 106 patients with newly diagnosed T2DM admitted to the hospital from May 2021 to April 2023.According to the random number table method,they were divided into observation group(n=53)and control group(n=53).The control group was treated with Metformin,while the observation group was treated with Dapagliflozin on the basis of that of the control group.The clinical efficacy,the levels of glucose metabolism indexes[2 h postprandial blood glucose(2hPG),glycosylated hemoglobin(HbAlc),fasting insulin(FINS),insulin resistance index(HOMA-IR),islet secretion index(HOMA-β)]and inflammatory factors[C-reactive protein(CRP),homocysteine(Hcy)],and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 94.34%(50/53),which was higher than 81.13%(43/53)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of HbAlc,2hPG and HOMA-IR in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the levels of FINS and HOMA-βin the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of CRP and Hcy in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Dapagliflozin combined with Metformin in the treatment of the newly diagnosed T2DM patients can improve the total effective rate of treatment,improve the levels of glucose metabolism indexes,and reduce the levels of inflammatory indicators.Moreover,it is superior to single Metformin treatment.
作者
张冬梅
ZHANG Dongmei(Department of Endocrinology of Shenqiu County People’s Hospital,Zhoukou 466300 Henan,China)
出处
《中国民康医学》
2024年第4期21-24,共4页
Medical Journal of Chinese People’s Health
关键词
达格列净
二甲双胍
2型糖尿病
糖代谢
炎性指标
不良反应
Dapagliflozin
Metformin
Type 2 diabetes
Glucose metabolism
Inflammatory indicators
Adverse reaction
